BearDownAZ

Thanks for the reply.

I had read the post from Sarah re: FDA approval status and several past posts from various authors speculating on reasons approval has not been obtained. The whole issue is troubling to me and IMHO the main reason for RVX's depressed market value. It seems to me that the recent deal with the Orient should have benchmarked the market value, but obviously the street thinks otherwise. If we refer to the recent targets posted by Zacks and Stonegate, RVX market value is yet significantly understated. The NPV of the RVX potential future revenue stream will significantly influence share price as we get closer to trial results but without FDA affirmation the outlook is cloudy as we continue to rely on the corporate pipeline.

Chicagoest